MedTrace Logo

Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma

NCT06912698 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 342

Last updated 2025-04-22

No results posted yet for this study

Summary

This study investigates whether administering reduced dose is non-inferior to standard dose radiotherapy in terms of 3-year locoregional relapse-free survival (LRRFS) rate for stage I nasopharyngeal carcinoma patients who are sensitive to radiotherapy.

Conditions

  • Nasopharyngeal Cancinoma (NPC)

Interventions

RADIATION

Reduced dose radiation

Reduced dose group would receive 61.48Gy radiation.

RADIATION

Standard dose radiation

Standard dose group would receive 69.96Gy radiation.

Sponsors & Collaborators

  • Hai-Qiang Mai,MD,PhD

    lead OTHER

Principal Investigators

  • Hai-Qiang MD, Dr. · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-22
Primary Completion
2031-04-19
Completion
2033-03-19
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06912698 on ClinicalTrials.gov